Compound | BEI | In Vitro Intrinsic Clbiliary | Plasma Unbound Fraction | Predicted Clbiliary | Estimated In Vivo Hepatic Clearance |
---|---|---|---|---|---|
% | ml/min/kg a | fu,p | ml/min/kg b | ml/min/kg c | |
Olmesartan | 34.6 ± 3.0 | 0.943 ± 0.330 | 0.01d | 0.00942 ± 0.00329 | 0.205 |
Valsartan | 23.0 ± 3.4 | 1.20 ± 0.33 | 0.059e | 0.0702 ± 0.0193 | 0.370 |
Pravastatin | 30.9 ± 3.1 | 0.484 ± 0.061 | 0.5f | 0.237 ± 0.029 | 7.20 |
Rosuvastatin | 24.6 ± 4.7 | 3.39 ± 0.89 | 0.12g | 0.390 ± 0.098 | 8.38 |
Pitavastatin | 15.6 ± 2.7 | 5.48 ± 1.21 | 0.004h | 0.0219 ± 0.0048 | No data |
↵ a In vitro intrinsic Clbiliary values were calculated according to eq. 2.
↵ b Predicted Clbiliary values were calculated according to eq. 3.
↵ c Estimated in vivo hepatic clearance values were calculated based on the difference between total clearance and renal clearance (see Materials and Methods).
↵ g Rosuvastatin regulatory documentation.
↵ h Pitavastatin regulatory documentation.